Most BRCA gene studies in ovarian cancer have centered around the differential chemosensitivity profile known as “BRCAness syndrome” in selected patients with inherited BRCA1 and BRCA2 mutations who are reported to show enhanced sensitivity to platinum-based anticancer drugs [10]. The gene discussed is BRCA1; the disease is ovarian cancer.